Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05228808
Other study ID # Soh-Med-22-01-30
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date February 1, 2022
Est. completion date December 1, 2022

Study information

Verified date January 2022
Source Sohag University
Contact Nagwa Ahmed, Lecturer
Phone 01017415996
Email nagwa.sadek@med.sohag.edu.eg
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Pancreatic carcinoma is ranked the 11th most common cancer worldwide. It is a highly lethal malignant tumor. In Egypt, the disease has traditionally been considered rare, but population in the East Nile Delta region exhibits an unusually high rate of young-onset pancreatic carcinoma. Pancreatic ductal adenocarcinoma is by far the most common histologic subtype of pancreatic malignancy. Programmed death ligand-1 (PD-L1) is a type I trans-membrane glycoprotein. It has an important prognostic and predictive value in various neoplasms. To date, few studies have addressed the potential prognostic role of PD-L1 in pancreatic carcinoma, so knowledge about its prognostic value needs further elucidation.


Description:

Pancreatic carcinoma is ranked the 11th most common cancer worldwide. It is a highly lethal malignant tumor with 5-year survival rate as low as 9%. It is the seventh leading cause of cancer-related deaths both in men and women worldwide. In Egypt, the disease has traditionally been considered rare, but population in the East Nile Delta region exhibits an unusually high rate of young-onset pancreatic carcinoma. Pancreatic ductal adenocarcinoma is by far the most common histologic subtype of pancreatic malignancy, accounting for about 90% of all pancreatic malignant neoplasms. Hence, the terms "pancreatic cancer" and "pancreatic ductal adenocarcinoma" are often used synonymously. Most pancreatic adenocarcinomas occur in the head of pancreas; about 60-70%. Tobacco smoking, diabetes mellitus, obesity, alcohol consumption, family history, certain genetic polymorphisms and chronic pancreatitis have been considered as risk factors for pancreatic adenocarcinoma. Pancreatic adenocarcinoma typically has a very poor prognosis. Although therapeutic strategies have been developed in recent years, the prognosis isn't significantly improved. To date, a group of prognostic factors are identified for clinical management of pancreatic adenocarcinoma. However, these markers are lack of accuracy to predict the outcome and aren't widely adopted. Therefore, it is still important to find out novel prognostic and predictive biomarkers to explore promising fields of research in terms of treatment selection and tailored therapy in pancreatic carcinoma. Immunotherapy is a rapidly growing field and represents a paradigm shift in the treatment of malignant tumors; it has made clinically significant breakthroughs in the last decade. Targeting immune checkpoints has had immense clinical success resulting in sustained treatment response for a subset of patients with certain malignancies. Currently, many clinical trials seek to assess the efficacy of immunotherapeutic strategies in pancreatic adenocarcinoma. Programmed death ligand-1 (PD-L1) is a type I trans-membrane glycoprotein. It acts as a ligand for Programmed death-1 (PD1) and has an important prognostic and predictive value in various types of neoplasms. It is overexpressed in several neoplasms such as bronchogenic carcinoma, hepatocellular carcinoma and breast cancer. PD1 and PD-L1 are immune checkpoints and members of cytotoxic T lymphocyte antigen-4 family. They are responsible for immunosuppression and decreased antitumor cytokines. They are expressed by tumor cells to escape immune surveillance. Moreover, PD1/PD-L1 pathway activates the intercellular signals that inhibit apoptosis and enhance survival of tumor cells. PD1 and PD-L1 are targeted in many clinical trials; blockade of the immune checkpoints activated by the PD-1/PD-L1 pathway has demonstrated impressive benefits in various neoplasms such as melanoma and non-small cell lung cancer. Blockade of PD-L1 is a prevalent strategy of cancer immunotherapy; the use of checkpoint inhibitors to target the PD1/PDL1 pathway results in breakthrough in the immunotherapy field. A number of studies investigated the association of PD-L1 and prognosis of pancreatic carcinoma, with controversial results presented [8]. To date, few studies have addressed the potential prognostic role of PD-L1 in pancreatic carcinoma, so knowledge about its prognostic value needs further elucidation. The aim of this study is to evaluate the expression of PD-L1 in pancreatic ductal adenocarcinoma and to correlate its expression to different studied histopathological parameters to evaluate its prognostic value.


Recruitment information / eligibility

Status Recruiting
Enrollment 50
Est. completion date December 1, 2022
Est. primary completion date June 1, 2022
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - Patients with pancreatic ductal adenocarcinoma who underwent surgery. Exclusion Criteria: - Patients received pre-operative chemotherapy or radiotherapy. - Patients with insufficient clinical data. - Specimens with extensive necrosis - Tiny specimens which are insufficient for accurate diagnosis.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Egypt Faculty of Medicine, Sohag University Sohag

Sponsors (1)

Lead Sponsor Collaborator
Sohag University

Country where clinical trial is conducted

Egypt, 

Outcome

Type Measure Description Time frame Safety issue
Primary evaluate the expression of PD-L1 in pancreatic ductal adenocarcinoma Immunohistochemical study 1 month
Primary correlate PD-L1 expression to different studied histopathological parameters to evaluate its prognostic value. Statistical analysis 1 month
See also
  Status Clinical Trial Phase
Completed NCT05305001 - Germline Mutations Associated With Hereditary Pancreatic Cancer in Unselected Patients With Pancreatic Cancer in Mexico
Recruiting NCT05059444 - ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Completed NCT01959672 - Chemotherapy, Stereotactic Body Radiation Therapy & Nelfinavir Mesylate in Locally Advanced Pancreatic Cancer Phase 2
Recruiting NCT03673423 - Evaluation of the Interobserver Agreement on the Resectability Status of Patients With a Pancreatic Cancer
Terminated NCT02495896 - Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors Phase 1
Recruiting NCT05351983 - Patient-derived Organoids Drug Screen in Pancreatic Cancer N/A
Not yet recruiting NCT06026943 - Alpha Radiation Emitters Device for the Treatment of Pancreatic Cancer Emitters for the Treatment of Locally Advanced Pancreatic Cancer N/A
Completed NCT03054987 - Endoscopic Ultrasound and Endoscopic Retrograde Cholangiopancreatography for Malignant Distal Biliary Obstruction N/A
Terminated NCT02345460 - Preoperative Folfirinox for Resectable Pancreatic Adenocarcinoma - A Phase II Study Phase 2
Recruiting NCT02072616 - Detection of Circulating Tumor Cells for the Diagnostic of Pancreatic Adenocarcinoma. Phase 3
Completed NCT02174887 - Biological Effect of Nab-paclitaxel Combined to Gemcitabine in Metastatic Pancreatic Cancer Phase 1
Recruiting NCT03703063 - Alternative Neoadjuvant Chemotherapy in Resectable and Borderline Resectable Pancreatic Cancer Phase 1
Terminated NCT04077372 - Assessment of a Serious Illness Conversation Guide (SICG) in Advanced Gastro-Intestinal Cancers N/A
Recruiting NCT03073785 - Hypofractionated Stereotactic Body Radiation & Fluorouracil or Capecitabine for Locally Advanced Pancreatic Cancer Phase 2
Completed NCT03665441 - Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment in PAC Phase 3
Recruiting NCT04627246 - Personalized Vaccine With SOC Chemo Followed by Nivo in Pancreatic Cancer Phase 1
Not yet recruiting NCT06217666 - Study Examining the Safety and Toxicity of Stereotactic Body Radiotherapy (SBRT) Followed by PCX12 Immunotherapy Delivered by Intratumoral Injection for the Treatment of Patients With Locally Advanced Pancreatic Adenocarcinoma (LAPC) Phase 1
Recruiting NCT05585320 - A Phase 1/2a Study of IMM-1-104 in Participants With Previously Treated, RAS-Mutant, Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Completed NCT04119362 - PARAGON Platform for Outcome, Quality of Life, and Translational Research on Pancreatic Cancer
Completed NCT03105921 - Irreversible Electroporation (NanoKnife) for the Treatment of Pancreatic Adenocarcinoma N/A